These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16626170)

  • 61. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
    de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
    Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Possible association between Budd-Chiari Syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia.
    Kurt M; Shorbagi A; Altundag K; Elkiran T; Güllü I; Kansu E
    Am J Hematol; 2005 Nov; 80(3):213-5. PubMed ID: 16247755
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin.
    Wijnen NE; Koedijk JB; Klein K; Luesink M; Goemans BF; Zwaan CM; Kaspers GJL
    Onco Targets Ther; 2023; 16():297-308. PubMed ID: 37153641
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML.
    Haag P; Viktorsson K; Lindberg ML; Kanter L; Lewensohn R; Stenke L
    Exp Hematol; 2009 Jun; 37(6):755-66. PubMed ID: 19463775
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Negative Impact of Gemtuzumab Ozogamicin on CD33-Positive Early T-Cell Precursor Acute Lymphoblastic Leukemia: A Case Report.
    Imataki O; Fujita H; Uemura M
    Case Rep Oncol; 2024; 17(1):256-261. PubMed ID: 38362442
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Gemtuzumab ozogamicin (GO) in relapsed/refractory patients with acute myeloid leukemia.
    Yamaguchi Y; Usui N; Dobashi N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Ogasawara Y; Saito T; Minami J; Kobayashi T; Katsube A; Kamiyama Y; Machishima T; Morikawa N; Otsubo H; Kaito K; Asai O; Aiba K
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1105-9. PubMed ID: 19620797
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia.
    Hååg P; Olsson M; Forsberg J; Lindberg ML; Stenerlöw B; Zong D; Kanter L; Lewensohn R; Viktorsson K; Zhivotovsky B; Stenke L
    Cell Death Discov; 2022 Jun; 8(1):284. PubMed ID: 35690610
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
    ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
    Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
    Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
    Taksin AL; Legrand O; Raffoux E; de Revel T; Thomas X; Contentin N; Bouabdallah R; Pautas C; Turlure P; Reman O; Gardin C; Varet B; de Botton S; Pousset F; Farhat H; Chevret S; Dombret H; Castaigne S
    Leukemia; 2007 Jan; 21(1):66-71. PubMed ID: 17051246
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Gemtuzumab-Ozogamicin-Related Impaired Hemoglobin-Haptoglobin Scavenging as On-Target/Off-Tumor Toxicity of Anti-CD33 AML Therapy: A Report of Two Cases.
    Rajala HLM; Anttila VJ; Haapio M; Keränen MAI; Wartiovaara-Kautto U; Räty R
    Case Rep Hematol; 2021; 2021():6641349. PubMed ID: 33824768
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients.
    McNerney KO; Oranges K; Seif AE; Oshrine B; Ky B; Lin KY; Getz KD; Aplenc R
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e507-e511. PubMed ID: 35200224
    [TBL] [Abstract][Full Text] [Related]  

  • 74. GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.
    Inase A; Maimaitili Y; Kimbara S; Mizutani Y; Miyata Y; Ohata S; Matsumoto H; Kitao A; Sakai R; Kawaguchi K; Higashime A; Nagao S; Kurata K; Goto H; Kawamoto S; Yakushijin K; Minami H; Matsuoka H
    EJHaem; 2023 Feb; 4(1):153-164. PubMed ID: 36819180
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML).
    Vegunta R; Harel R; Steinberg A
    Cureus; 2022 Jun; 14(6):e26240. PubMed ID: 35898381
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gemtuzumab Ozogamicin Treatment Results in Decreased Proliferation and Differentiation of Human Megakaryocytes but Does Not Inhibit Mature Platelet Function.
    Vitsky A; Sacaan A; Hu W; Finkelstein M; Reagan W
    Toxicol Pathol; 2022 Oct; 50(7):871-880. PubMed ID: 36200575
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin.
    Molica M; Perrone S; Mazzone C; Niscola P; Cesini L; Abruzzese E; de Fabritiis P
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34203180
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.
    Godwin CD; Rodríguez-Arbolí E; Othus M; Halpern AB; Appelbaum JS; Percival MM; Hendrie PC; Oehler VG; Keel SB; Abkowitz JL; Cooper JP; Cassaday RD; Estey EH; Walter RB
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740603
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Novel monoclonal antibody-based therapies for acute myeloid leukemia.
    Morsink LM; Walter RB
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):116-126. PubMed ID: 31203993
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.
    Mizutani Y; Inase A; Maimaitili Y; Miyata Y; Kitao A; Matsumoto H; Kawaguchi K; Higashime A; Goto H; Kurata K; Yakushijin K; Minami H; Matsuoka H
    Int J Hematol; 2019 Oct; 110(4):490-499. PubMed ID: 31286402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.